Clinical trials: Exacerbations
Asthma
The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations
This study is looking at the effects of certain long-acting bronchodilators on patients with asthma who have specific genetic variations.
- Trial name
- GABLE (NCT00706446)
- Testing
- tiotropium bromide, Salmeterol, Formoterol
- Where
- 2 sites in United States
- Volunteers
- 255 people
- Sponsor
- Brigham and Women's Hospital
Pulmonary Embolism, Chronic Obstructive Pulmonary Disease
Pulmonary Embolism as a Cause of COPD Exacerbations
The primary objective is to demonstrate the clinical benefits of an active strategy for the diagnosis and treatment of PE compared to usual care in patients with unexplained exacerbations of COPD who require hospital admission.
- Trial name
- SLICE (NCT02238639)
- Testing
- Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).
- Where
- 19 sites in Spain
- Volunteers
- 746 people
- Sponsor
- Ministry of Health, Spain
Asthma
(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)
Asthma is a common, serious illness among children in the United States. It can be effectively controlled through the use of preventative medications and "rescue" medications, which are used to control symptoms.
- Trial name
- TREXA (NCT00394329)
- Testing
- Beclomethasone dipropionate, Albuterol sulfate
- Where
- 6 sites in United States
- Volunteers
- 288 people
- Sponsor
- Milton S. Hershey Medical Center
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this study is to compare the efficacy and safety of BCT197 when added on to standard of care in adult subjects with acute respiratory exacerbations of chronic obstructive pulmonary disease requiring…
- Trial name
- NCT02700919
- Testing
- BCT197
- Where
- 46 sites in United States, Bulgaria and 8 more
- Volunteers
- 282 people
- Sponsor
- Mereo BioPharma
Asthma
Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)
We are doing this study to learn how genes affect the way that people, specifically Black people, respond to treatment for asthma.
- Trial name
- BELT (NCT01290874)
- Testing
- Tiotropium, Salmeterol, Formoterol
- Where
- 13 sites in United States
- Volunteers
- 1,070 people
- Sponsor
- Brigham and Women's Hospital
Chronic Obstructive Pulmonary Disease
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
- Trial name
- SPARK (NCT01120691)
- Testing
- QVA149, NVA237, tiotropium
- Where
- 342 sites in United States, Argentina and 26 more
- Volunteers
- 2,224 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)
The study estimates the efficacy and safety of MK0476 and aminophylline intravenous administration in adult participants with acute asthma.
- Trial name
- NCT00442338
- Testing
- montelukast sodium, aminophylline hydrate
- Volunteers
- 91 people
- Sponsor
- Organon and Co
Cystic Fibrosis, Pneumonia
Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
This study will determine the concentrations of the antibiotic meropenem when administered as a 3 hour prolonged infusion in children with cystic fibrosis who are hospitalized with an acute pulmonary exacerbation.
- Conditions
- Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
- Trial name
- NCT01429259
- Testing
- meropenem
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Joseph Kuti
Asthma
Exacerbations in Severe Asthma Patients: Mechanisms and Biomarkers
The purpose of this study is to investigate exacerbations in severe asthma with regard to symptoms, lung function, aetiology and biomarkers.
- Trial name
- NCT02660853
- Testing
- FEV1
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Imperial College London
Pulmonary Disease, Chronic Obstructive
The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.
This non-Interventional, descriptive, cross-sectional cohort and multicentre study will be conducted with COPD patients attended at Spanish Primary Care offices.
- Trial name
- NCT03611777
- Testing
- Inhaled corticosteroid
- Where
- 169 sites in Spain
- Volunteers
- 901 people
- Sponsor
- Boehringer Ingelheim
Non-Cystic Fibrosis Bronchiectasis
Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis
Objective: To evaluate whether long-term oral N-acetylcysteine as an expectorant drug can reduce the frequency of acute exacerbations of patients with non-cystic fibrosis bronchiectasis and improve their quality of life.
- Trial name
- BENE (NCT02088216)
- Testing
- N-acetylcysteine, On-demand treatment
- Where
- China
- Volunteers
- 161 people
- Sponsor
- Qilu Hospital of Shandong University
Chronic Obstructive Pulmonary Disease
Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study
The aim of this multi-centre, double blind, randomised, controlled trial (DBRCT) is to assess the effect of low dose theophylline, singly and in combination with low dose oral prednisone, on COPD (Chronic Obstructive Pulmonary…
- Trial name
- TASCS (NCT02261727)
- Testing
- Theophylline, Prednisone
- Where
- Australia
- Volunteers
- 1,670 people
- Sponsor
- The George Institute
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01009463
- Testing
- FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Where
- 188 sites in United States, Argentina and 13 more
- Volunteers
- 1,626 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Danirixin (DNX) is a selective CXC chemokine receptor (CXCR2) antagonist being developed as a potential anti-inflammatory agent for the treatment of COPD. This is a Phase 2, randomized, double-blind (Sponsor Open) study.
- Trial name
- NCT03034967
- Testing
- Danirixin, Standard of care, Rescue medication
- Where
- 64 sites in United States, Australia and 7 more
- Volunteers
- 614 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is caused by cigarette smoking or by breathing in other lung irritants, including pollution, dust, or chemicals.
- Trial name
- LEUKO (NCT00493974)
- Testing
- Zileuton
- Where
- 18 sites in United States
- Volunteers
- 119 people
- Sponsor
- University of Minnesota
Cystic Fibrosis
Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations
Gastroesophageal reflux disease (GERD) is a common problem in cystic fibrosis (CF). It may lead to worsening lung function and more respiratory infections for a person with CF.
- Trial name
- NCT01983774
- Testing
- Esomeprazole
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Columbia University
COPD, Chronic Obstructive Pulmonary Disease
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
The Objectives of this study are to assess the safety of Aclidinium bromide on major adverse cardiovascular events (MACE), to assess the overall safety of Aclidinium bromide and to assess whether Aclidinium bromide reduces…
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
- Trial name
- ASCENT COPD (NCT01966107)
- Testing
- Aclidinium Bromide
- Where
- 468 sites in United States, Canada
- Volunteers
- 3,635 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group trial evaluating mepolizumab 100 mg against placebo given every 4 weeks through subcutaneous (SC) injection.
- Trial name
- NCT02105948
- Testing
- Mepolizumab
- Where
- 116 sites in United States, Australia and 14 more
- Volunteers
- 837 people
- Sponsor
- GlaxoSmithKline
COPD Exacerbation
COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers
The purpose of this study is to compare drug delivery and lung function after treatment with formoterol from a nebulizer versus a dry powder inhaler (DPI) in patients recovering from severe exacerbations of COPD.
- Trial name
- NCT02291016
- Testing
- Formoterol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Tennessee Graduate School of Medicine
COPD
Efficacy and Safety of AQX-1125 in Unstable COPD
The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo in subjects following exacerbations of Chronic Obstructive Pulmonary Disease…
- Trial name
- FLAGSHIP (NCT01954628)
- Testing
- AQX-1125
- Where
- 8 sites in United States, Australia and 6 more
- Volunteers
- 400 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.